Drugs / Bivalent subtype C gp120/MF59
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03122223 Comparator | Jan 2018 → Jul 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent subtype C gp120/MF59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03122223 ↗ |
| Route | Intramuscular | “administered IM as a single 0.5 mL dose” NCT03122223 ↗ |